Viewing Study NCT04148092


Ignite Creation Date: 2025-12-24 @ 3:25 PM
Ignite Modification Date: 2025-12-26 @ 9:35 PM
Study NCT ID: NCT04148092
Status: APPROVED_FOR_MARKETING
Last Update Posted: 2020-05-29
First Post: 2019-10-30
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST
Sponsor: Deciphera Pharmaceuticals, LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module References Module